AXA/2025/FY/Earnings presentation: Difference between revisions
Content deleted Content added
PlumBot: publish from draft |
Migrate infobox: document_type -> document_category; add specific form as document_type |
||
| (2 intermediate revisions by the same user not shown) | |||
Line 4:
| period = FY
| period_label = FY25
|
| publication_date = 2026-02-26
| language = English
Line 18:
=== Full Year 2025 earnings presentation ===
* ''
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures ===
* ''
*
*
* ''
** APMs are defined under ESMA guidelines and the AMF's 2015 position statement, with reconciliations provided in AXA's 2025 Activity Report <sup>p. 2</sup>.
* ''Financial statements status'': AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of audit procedures <sup>p. 2</sup>.
=== Table of contents ===
*
*
*
== FY25 Highlights ==
*
=== Full Year 2025 | Excellent performance ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Key financial highlights, FY25 <sup>p. 5</sup>
! style="text-align:left" | Metric
! class="col-
|-
| style="text-align:left" | Revenues growth vs. FY24
|
|-
| style="text-align:left" | Underlying EPS growth vs. FY24
|
|-
| style="text-align:left" | Return on equity
|
|-
| style="text-align:left" | Solvency II ratio
|
|-
| style="text-align:left" |
|
|-
| style="text-align:left" |
|
|-
| style="text-align:left" | Underlying EPS
|
|}
</div>
*
* Share buyback approved by the Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable, subject to market conditions
=== Executing the plan on growth, margin and efficiency ===
Line 79 ⟶ 80:
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
! class="col-s" style="text-align:right" | Change (excluding AXA IM)
|-
| style="text-align:left" | Underlying earnings
Line 89 ⟶ 90:
|}
</div>
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency
* Scaling the business: Continued investments in growth and technology
* Consistent earnings growth while enhancing reserve prudence
=== Diversified franchise, well positioned in an attractive industry ===
Line 99:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+
! style="text-align:left" | Segment
! class="col-s" style="text-align:right" | Share
Line 110:
|-
| style="text-align:left" | Large & Specialty
| style="text-align:right" | 17%
|-
| style="text-align:left" | Retail
| style="text-align:right" | 17%
|-
| style="text-align:left" | SME & Mid-market
| style="text-align:right" | 16%
|}
</div>
* ''Secular trends''
* ''Our right to win'' is supported by four
** Leading brand & high customer NPS
** Strong and diversified distribution
** Technical expertise to price & underwrite risks
** Scale offering cost advantage
=== Laying the foundation for the next plan ===
*
** ''Clear tech'' and AI roadmap <sup>p. 8</sup>
** ''Driving efficiency'' across operations <sup>p. 8</sup>
** ''Enhancing capital'' allocation discipline <sup>p. 8</sup>
** ''Building resilience'' across the business <sup>p. 8</sup>
*
== Business Performance ==
Line 140:
=== FY25 business performance ===
*
=== Strong delivery across our businesses ===
*
*
*
<div style="overflow-x:auto">
{| class="wikitable"
|+
! style="text-align:left" | Region (share of total GWP¹)
! class="col-m" style="text-align:right" | Gross written premiums
! class="col-m" style="text-align:right" | Underlying earnings
|-
| style="text-align:left" | ''France'' (27% of total GWP¹)
| class="col-m" style="text-align:right" | +6% to EUR 31bn
| class="col-m" style="text-align:right" | +7% to EUR 2.2bn
|-
| style="text-align:left" | ''Europe'' (38% of total GWP¹)
| class="col-m" style="text-align:right" | +6% to EUR 43bn
| class="col-m" style="text-align:right" | +9% to EUR 3.5bn
|-
| style="text-align:left" | ''AXA XL'' (17% of total GWP¹)
| class="col-m" style="text-align:right" | +4% to EUR 19bn
| class="col-m" style="text-align:right" | +9% to EUR 1.9bn
|-
| style="text-align:left" | ''Asia, Africa & EME-LATAM'' (18% of total GWP¹)
| class="col-m" style="text-align:right" | +13% to EUR 20bn
| class="col-m" style="text-align:right" | +6% to EUR 1.5bn
Line 175:
=== P&C | Strong margins, confidence in sustaining growth ===
*
* (donut)
**
* ''Underlying earnings'' +9% at constant FX to EUR 5.9bn <sup>p. 11</sup>.
* ''Retail and SME & Mid-market'' strategic outlook:
** ''
** ''Beyond 2025'': Investing to improve customer retention and expanding distribution footprint <sup>p. 11</sup>.
* ''AXA XL (Large & Specialty)'' strategic outlook:
** ''
** ''Beyond 2025'': Capitalizing on attractive growth opportunities and continued cycle management <sup>p. 11</sup>.
* ''Earnings drivers'' supporting performance:
** Continued progress on efficiency <sup>p. 11</sup>.
** Higher investment income <sup>p. 11</sup>.
Line 191 ⟶ 192:
=== L&H | Good momentum, well positioned to capture growth opportunities ===
* ''Gross written premiums'' (GWP) reached EUR 57bn <sup>p. 12</sup>.
* (donut) ''GWP mix'': Short-term and Long-term segments — shares not labeled <sup>p. 12</sup>.
* ''Underlying earnings'' +7% LFL to EUR 3.5bn (change FY25 vs. FY24 at constant FX) <sup>p. 12</sup>.
* ''Long-term business'' strategic priorities:
** ''2025'': Accelerating net flows in Savings at attractive margins <sup>p. 12</sup>.
** ''Beyond 2025'': Capturing savings & retirement opportunity, sourcing best asset management products for our customers <sup>p. 12</sup>.
* ''Short-term business'' strategic priorities:
** ''2025'': Growing technical results while absorbing Mexico VAT impact <sup>p. 12</sup>.
** ''Beyond 2025'': Capitalizing on demand for health & protection while further improving our margins <sup>p. 12</sup>.
* ''Strategic levers'' for growth and efficiency:
** Focus on cost reduction <sup>p. 12</sup>.
** Increasing penetration of Protection riders in Savings offerings <sup>p. 12</sup>.
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health <sup>p. 12</sup>.
== Financial Performance ==
Line 221 ⟶ 210:
=== FY25 financial performance ===
*
=== P&C | Continued disciplined growth ===
Line 227 ⟶ 216:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ P&C GWP
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
! class="col-s" style="text-align:right" | o/w pricing
! class="col-s" style="text-align:right" | o/w volume
Line 264 ⟶ 253:
|}
</div>
*
*
*
*
=== P&C | Delivering further margin expansion while enhancing reserve prudence ===
Line 273 ⟶ 262:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Combined ratio
! style="text-align:left" | Combined ratio
! class="col-s" style="text-align:right" | FY24
Line 303 ⟶ 292:
|}
</div>
*
** Margin expansion in
** Stable
*
*
*
*
=== P&C | Earnings growth from higher underwriting and financial result ===
Line 344 ⟶ 333:
|}
</div>
* Underlying earnings grew +9% at constant FX to EUR 5,872m
* Underwriting result
* Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets.
* Insurance finance expenses impacted by higher unwind of discount of claims reserves, in line with guidance.
* Forex impact was unfavorable, notably due to USD depreciation vs. EUR.
=== Life & Health | Strong growth in premiums, positive net flows ===
Line 356 ⟶ 343:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left" | Life GWP
| style="text-align:right" | 34.5
| style="text-align:right" | 37.5
| style="text-align:right" | +9%
|-
| style="text-align:left" | Protection
Line 382 ⟶ 374:
| style="text-align:right" | -7%
|-
| style="text-align:left
| style="text-align:right
| style="text-align:right
| style="text-align:right
|-
| style="text-align:left" | Individual
Line 407 ⟶ 389:
| style="text-align:right" | +4%
|-
| style="text-align:left
| style="text-align:right
| style="text-align:right
| style="text-align:right
|}
</div>
Line 416 ⟶ 398:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Net flows by segment, FY24 vs FY25 <sup>p. 17</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left; font-weight:bold" | Total
| style="text-align:right; font-weight:bold" | 1.5
| style="text-align:right; font-weight:bold" | 5.4
|-
| style="text-align:left" | Protection
| style="text-align:right" |
| style="text-align:right" | 4.9
|-
| style="text-align:left" | Health
| style="text-align:right" |
| style="text-align:right" | 2.7
|-
| style="text-align:left" | Unit-Linked
| style="text-align:right" |
| style="text-align:right" | 1.5
|-
| style="text-align:left" | Capital light G/A
| style="text-align:right" |
| style="text-align:right" | 1.2
|-
| style="text-align:left" | Traditional G/A
| style="text-align:right" | —
| style="text-align:right" | -5.0
|}
</div>
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting ===
Line 443 ⟶ 433:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ PVEP trend by segment, FY24 vs FY25 <sup>p. 18</sup>
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left; font-weight:bold" | Total PVEP
| style="text-align:right; font-weight:bold" | 50.9
| style="text-align:right; font-weight:bold" | 49.4
| style="text-align:right; font-weight:bold" | -2%
|-
| style="text-align:left" | Protection & Health
Line 468 ⟶ 463:
| style="text-align:right" | 1.7
| style="text-align:right" | -10%
|}
</div>
Line 478 ⟶ 468:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ NB CSM
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | LFL Change
|-
| style="text-align:left" |
| style="text-align:right" | 2.2
| style="text-align:right" | 2.2
| style="text-align:right" | +3%
|-
| style="text-align:left" | NBV (post-tax)
| style="text-align:right" | 2.3
| style="text-align:right" | 2.2
| style="text-align:right" | stable
|}
</div>
* ''PVEP'' impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup>.
* ''NB CSM'' driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits <sup>p. 18</sup>.
* ''NBV'' broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup>.
* ''NBV margin'': 4.4% in FY24 → 4.5% in FY25 <sup>p. 18</sup>
=== Life & Health | Growth in new business driving Normalized CSM growth ===
Line 519 ⟶ 497:
|+ Contractual Service Margin rollforward, FY24 to FY25 <sup>p. 19</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | FY24
Line 547 ⟶ 525:
</div>
* ''Normalized CSM'' up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup>
* ''Economic variance'' reflecting government spreads tightening and positive equity market returns <sup>p. 19</sup>
* ''Operating variance'' driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup>
* ''FX impact'' mainly from JPY and HKD depreciation <sup>p. 19</sup>
* (waterfall) ''Contractual Service Margin rollforward'' (in EUR billion): FY24 EUR 33.6bn (o/w Life EUR 25.8bn, o/w Health EUR 7.7bn) → New business CSM +EUR 2.2bn → Underlying return on in-force +EUR 1.3bn → CSM release -EUR 3.0bn (Normalized CSM growth +2%) → Economic variance +EUR 0.6bn → Operating variance -EUR 0.3bn → Affiliates, FX & other -EUR 1.4bn → FY25 EUR 33.0bn (o/w Life EUR 25.4bn, o/w Health EUR 7.6bn) <sup>p. 19</sup>
=== Life & Health | Strong momentum in both short-term and long-term business ===
Line 575 ⟶ 536:
{| class="wikitable fintable"
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 20</sup>
! style="text-align:left" | EUR million
! class="col-s" style="text-align:right" | Underlying earnings
|-
| style="text-align:left" | FY24 start
| style="text-align:right" | 3,323
|-
Line 593 ⟶ 554:
| style="text-align:right" | -27
|-
| style="text-align:left" | FY25 end
| style="text-align:right" | 3,501
|}
</div>
* ''Underlying earnings'' +7% LFL to EUR 3,501m <sup>p. 20</sup>
* ''Short-term technical margin'': EUR 415m in FY24 to EUR 479m in FY25 <sup>p. 20</sup>
* ''Long-term result'' incl. CSM release: EUR 2,680m in FY24 to EUR 2,804m in FY25 <sup>p. 20</sup>
* ''Financial result'': EUR 975m in FY24 to EUR 946m in FY25 <sup>p. 20</sup>
* ''Tax & others'': EUR -748m in FY24 to EUR -728m in FY25 <sup>p. 20</sup>
* ''Life underlying earnings'' +4% to EUR 2.7bn (prior: EUR 2.6bn) <sup>p. 20</sup>
* ''Health underlying earnings'' +17% to EUR 0.8bn (prior: EUR 0.7bn) <sup>p. 20</sup>
* ''Short-term margin'' strong on underwriting and claims initiatives; more than offset legislative change on Mexico VAT recoverability of EUR -0.1bn <sup>p. 20</sup>
* ''Long-term results'' higher from CSM release increase of +8% on reserve base growth, favorable equity markets, and better margins <sup>p. 20</sup>
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM ===
Line 651 ⟶ 573:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Earnings and net income breakdown
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
Line 677 ⟶ 599:
| style="text-align:right" | -
|-
| style="text-align:left" | ''Underlying earnings''
| style="text-align:right" | 8.1
| style="text-align:right" | 8.4
Line 697 ⟶ 619:
| style="text-align:right" | —
|-
| style="text-align:left" | ''Net income''
| style="text-align:right" | 7.9
| style="text-align:right" | 9.8
Line 706 ⟶ 628:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying earnings per share
! style="text-align:left" | EUR
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" |
| style="text-align:right" | 3.59
|-
| style="text-align:left" | Earnings growth
Line 734 ⟶ 644:
| style="text-align:right" | -2%
|-
| style="text-align:left" | Temporary earnings dilution from AXA IM sale
| style="text-align:right" | -1%
|-
| style="text-align:left" | FY25
| style="text-align:right" | 3.86
|}
</div>
*
** Strong performance from insurance businesses <sup>p. 21</sup>
** Stable holding cost, expected to remain at current level in 2026 <sup>p. 21</sup>
*
** Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM <sup>p. 21</sup>
** Lower financial flows reflecting unfavorable forex impact <sup>p. 21</sup>
* Change is at constant FX for underlying earnings and net income; change is on a reported basis for underlying earnings per share <sup>p. 21</sup>
* (bar) ''Underlying earnings per share'' (In Euro): EUR 3.59 in FY24 to EUR 3.86 in FY25 (+8%) <sup>p. 21</sup>
=== Shareholders' equity ===
* (stacked bar) ''Shareholders' equity'' Group share:
** ''FY24'': EUR 49.9bn total (comprising SHE excl. OCI EUR 58.0bn and Net OCI EUR -8.1bn) <sup>p. 22</sup>
** ''FY25'': EUR 47.2bn total (comprising SHE excl. OCI EUR 54.0bn and Net OCI EUR -6.8bn) <sup>p. 22</sup>
* ''SHE (excl. OCI & undated subordinated debt)'': EUR 53.2bn in FY24 → EUR 47.0bn in HY25 → EUR 49.4bn in FY25 <sup>p. 22</sup>
* ''Debt gearing'': 20.6% in FY24 → 23.4% in HY25 → 22.3% in FY25 <sup>p. 22</sup>
* ''Underlying ROE'': 15.2% in FY24 → 17.5% in HY25 → 16.0% in FY25 <sup>p. 22</sup>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Shareholders' equity roll-forward
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY24 to FY25
! class="col-s" style="text-align:right" | HY25 to FY25
|-
| style="text-align:left" |
| style="text-align:right" | 49.9
| style="text-align:right" | 45.5
Line 831 ⟶ 714:
| style="text-align:right" | 0.3
|-
| style="text-align:left" |
| style="text-align:right" | 47.2
| style="text-align:right" | 47.2
|}
</div>
=== Higher organic cash remittance and robust cash position at Holding ===
*
**
** ''
* ''Remittance ratio'' remained stable at 82% in FY24 and 82% in FY25, based on ordinary cash remittance of EUR 7.1bn in FY24 and EUR 7.5bn in FY25 <sup>p. 23</sup>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Holding cash position bridge FY24 to FY25
! style="text-align:left" |
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | ''FY24 Cash position''
| style="text-align:right" | 4.0
|-
| style="text-align:left" | Net cash remittance from subsidiaries
Line 871 ⟶ 757:
| style="text-align:right" | +3.1
|-
| style="text-align:left" | ''FY25 Cash position''
| style="text-align:right" | 5.6
|}
Line 928 ⟶ 814:
</div>
* Foreseeable dividends accounted for -EUR 4.8bn.
* Provision for annual share buyback for 2026 accounted for -EUR 1.25bn.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Key sensitivities of Solvency II ratio as of December 31, 2025 (base 224%) <sup>p. 24</sup>
! style="text-align:left" | Sensitivity
! class="col-s" style="text-align:right" | Impact (pts)
Line 951 ⟶ 838:
| style="text-align:right" | -4
|-
| style="text-align:left" | Listed Equity (
| style="text-align:right" | -1
|-
| style="text-align:left" | Listed Equity (
| style="text-align:right" | +2
|-
Line 968 ⟶ 855:
</div>
* Euro sovereign spreads sensitivity assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve, applied on sovereign and quasi-sovereign exposures.
*
=== Solvency II -impact of the end of grandfathering period and Solvency II revision ===
Line 977 ⟶ 863:
{| class="wikitable fintable"
|+ Solvency II ratio impacts <sup>p. 25</sup>
! style="text-align:left" |
! class="col-
|-
| style="text-align:left" |
| style="text-align:right" | 224
|-
| style="text-align:left" | Grandfathering end impact on January 1, 2026
| style="text-align:right" | -
|-
| style="text-align:left" | Solvency II revision impact to come into effect in 1Q27
| style="text-align:right" | +
|}
</div>
* EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026
* No change is expected in organic capital generation.
* Provides additional capital flexibility.
* Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.
* ''Grandfathering end impact'' on January 1, 2026 is -10pts to 215% <sup>p. 25</sup>.
=== Thomas Buberl, Group CEO conclusion ===
* ''
=== Conclusion ===
*
* ''
*
* ''
=== February 26, 2026 Q&A Full Year 2025 earnings ===
* ''
=== AXA Investor Relations | Keep in touch ===
*
*
<div style="overflow-x:auto">
{| class="wikitable"
|+ Meet our management event
! style="text-align:left" | Date
! class="col-m" style="text-align:right" | Event
Line 1,052 ⟶ 938:
== Appendices ==
* Section divider
=== Table of contents ===
*
*
*
*
=== Gross financial debt and maturity breakdown as of December 31st, 2025 ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Gross financial debt <sup>p. 32</sup>
! style="text-align:left" | EUR billion unless otherwise mentioned
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Jan 1st 2026
|-
| style="text-align:left" | Tier 1
| style="text-align:right" | 4.8
| style="text-align:right" | 4.6
| style="text-align:right" | 3.2
|-
| style="text-align:left" | Tier 2
| style="text-align:right" | 10.8
| style="text-align:right" | 12.2
| style="text-align:right" | 11.3
|-
| style="text-align:right" | 3.5
| style="text-align:right" | 3.5
| style="text-align:right" | 5.8
|-
| style="text-align:left; font-weight:bold" | Total
| style="text-align:right; font-weight:bold" | 19.2
| style="text-align:right; font-weight:bold" | 20.3
| style="text-align:right; font-weight:bold" | 20.3
|-
| style="text-align:left" | Debt gearing
| style="text-align:right" | 20.6%
| style="text-align:right" | 22.3%
| style="text-align:right" | —
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Contractual maturity breakdown <sup>p. 32</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | Tier 1
! class="col-s" style="text-align:right" | Tier 2
! class="col-s" style="text-align:right" | Senior debt
|-
| style="text-align:left" | 2028
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 0.5
|-
| style="text-align:left" | 2030
| style="text-align:right" | —
| style="text-align:right" | 0.7
| style="text-align:right" | 0.9
|-
| style="text-align:left" | 2031-2039
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 1.5
|-
| style="text-align:left" | ≥2040
| style="text-align:right" | —
| style="text-align:right" | 10.8
| style="text-align:right" | 0.5
|-
| style="text-align:left" | Undated
| style="text-align:right" | 4.6
| style="text-align:right" | 0.7
| style="text-align:right" | —
|-
| style="text-align:left" | Grandfathered debt (contractual)
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1 Undated
| style="text-align:right" | 1.4
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 2 2030
| style="text-align:right" | —
| style="text-align:right" | 0.7
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 2 ≥2040
| style="text-align:right" | —
| style="text-align:right" | 0.2
| style="text-align:right" | —
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Economic maturity breakdown <sup>p. 32</sup>
! style="text-align:left" | EUR billion
! class="col-s" style="text-align:right" | Tier 1
! class="col-s" style="text-align:right" | Tier 2
! class="col-s" style="text-align:right" | Senior debt
|-
| style="text-align:left" | 2026
| style="text-align:right" | 0.1
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | 2027
| style="text-align:right" | —
| style="text-align:right" | 2.4
| style="text-align:right" | —
|-
| style="text-align:left" | 2028
| style="text-align:right" | 0.1
| style="text-align:right" | —
| style="text-align:right" | 0.5
|-
| style="text-align:left" | 2029
| style="text-align:right" | —
| style="text-align:right" | 2.0
| style="text-align:right" | —
|-
| style="text-align:left" | 2030
| style="text-align:right" | —
| style="text-align:right" | 0.7
| style="text-align:right" | 0.9
|-
| style="text-align:left" | 2031-2039
| style="text-align:right" | 0.4
| style="text-align:right" | 6.4
| style="text-align:right" | 1.5
|-
| style="text-align:left" | ≥2040
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 0.5
|-
| style="text-align:left" | Undated
| style="text-align:right" | 4.0
| style="text-align:right" | 0.7
| style="text-align:right" | —
|-
| style="text-align:left" | Grandfathered debt (economic)
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1 2026
| style="text-align:right" | 0.1
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1 2028
| style="text-align:right" | 0.1
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1 2031-2039
| style="text-align:right" | 0.4
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1 Undated
| style="text-align:right" | 0.8
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 2 2030
| style="text-align:right" | —
| style="text-align:right" | 0.7
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 2 ≥2040
| style="text-align:right" | —
| style="text-align:right" | 0.2
| style="text-align:right" | —
|}
</div>
* In January 2026, AXA called the remaining Tier 2 grandfathered GBP 139m due 2054 callable 2034 (5.625% issued January 2014) and the Tier 1 grandfathered EUR 250m perpetual callable 2010 floating (issued January 2005).
* Economic maturity accounts for the first date of step-up calls on institutionally placed subordinated debt.
* For Solvency II RT1 debt with no step-up, the undated nature of the instrument is retained for economic maturity.
=== General account invested assets ===
*
*
* (donut)
* ''Other fixed income'' includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) <sup>p. 33</sup>.
* ''Listed equities'' includes hedges; listed equities excluding hedges at EUR 14bn <sup>p. 33</sup>.
* ''Private equity and hedge funds'' includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) <sup>p. 33</sup>.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Invested assets
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | %
|-
| style="text-align:left" |
| style="text-align:right" | 345
| style="text-align:right" | 77%
Line 1,112 ⟶ 1,156:
| style="text-align:right" | 27%
|-
| style="text-align:left" | ''o/w Other fixed income
| style="text-align:right" | 56
| style="text-align:right" | 13%
|-
| style="text-align:left" |
| style="text-align:right" | 41
| style="text-align:right" | 9%
|-
| style="text-align:left" |
| style="text-align:right" | 10
| style="text-align:right" | 2%
|-
| style="text-align:left" |
| style="text-align:right" | 10
| style="text-align:right" | 2%
|-
| style="text-align:left" |
| style="text-align:right" | 23
| style="text-align:right" | 5%
|-
| style="text-align:left" |
| style="text-align:right" | 19
| style="text-align:right" | 4%
|-
| style="text-align:left" |
| style="text-align:right" | 2
| style="text-align:right" | 0%
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
|}
</div>
=== Structured and private credit assets ===
* ''Total structured and private credit assets'' stood at EUR 69bn, representing 15% of the total General Account portfolio, with 54% participating <sup>p. 34</sup>.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Structured and
! style="text-align:left" | Invested assets (100%)
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | % of total G/A¹ portfolio
Line 1,183 ⟶ 1,225:
| style="text-align:right" | 10
| style="text-align:right" | 2%
| style="text-align:right" | - Strong diversification with EUR 8m average ticket - Investments through SMAs with strict underwriting guidelines
|-
| style="text-align:left" | Other
Line 1,190 ⟶ 1,232:
| style="text-align:right" | —
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | o/w 54% participating
|}
</div>
*
=== Investment portfolio | Fixed income reinvestment ===
Line 1,203 ⟶ 1,245:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 Fixed
! style="text-align:left" | Asset mix
! class="col-s" style="text-align:right" | Share
Line 1,223 ⟶ 1,265:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 Fixed
! style="text-align:left" | Fixed
! class="col-s" style="text-align:right" | Yield
|-
Line 1,237 ⟶ 1,279:
|}
</div>
* Fixed income reinvestment totaled EUR 57bn in FY25 <sup>p. 35</sup>
* Reinvestment yield achieved at 3.9% on EUR 57bn fixed income <sup>p. 35</sup>
** Average duration of 9 years <sup>p. 35</sup>
** Private & Structured Credit reinvestment of EUR 19.7bn at 4.7% yield, including CLOs, ABS, Infra & CRE debt, Fund financing, and Private HY <sup>p. 35</sup>
** Strategic shift characterized by a gradual transition from alternative total return assets to Private & Structured credit <sup>p. 35</sup>
=== Table of contents ===
* ''Debt and Invested Assets'' on page 31 <sup>p. 36</sup>
* ''Additional P&C disclosures'' on page 36 <sup>p. 36</sup>
* ''Additional IFRS17 disclosures'' on page 41 <sup>p. 36</sup>
* ''Sustainability'' on page 44 <sup>p. 36</sup>
=== AXA XL Insurance | Large Commercial & Specialty business ===
Line 1,251 ⟶ 1,297:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ FY25 GWP
! style="text-align:left" |
! class="col-s" style="text-align:right" | Share
|-
Line 1,272 ⟶ 1,318:
{| class="wikitable fintable"
|+ FY25 GWP by geography <sup>p. 37</sup>
! style="text-align:left" |
! class="col-s" style="text-align:right" | Share
|-
Line 1,286 ⟶ 1,332:
</div>
<div style="overflow-x:auto">
{| class="wikitable"
|+ Profitability vs Ex-price growth (%) <sup>p. 37</sup>
! style="text-align:left" | Line of business
! class="col-m" style="text-align:right" | Profitability
! class="col-m" style="text-align:right" | Ex-price growth
|-
| style="text-align:left" | Property
| class="col-m" style="text-align:right" | high
| class="col-m" style="text-align:right" | high
|-
| style="text-align:left" | Specialty
| class="col-m" style="text-align:right" | medium-high
| class="col-m" style="text-align:right" | medium-high
|-
| style="text-align:left" | Casualty
| class="col-m" style="text-align:right" | medium
| class="col-m" style="text-align:right" | medium
|-
| style="text-align:left" | Professional lines
| class="col-m" style="text-align:right" | lower
| class="col-m" style="text-align:right" | lower
|}
</div>
* Business diversification is well balanced across lines of business and geographies <sup>p. 37</sup>
* Market leadership positions AXA XL in the top 3 globally for <sup>p. 37</sup>:
** Multinational Programs <sup>p. 37</sup>
** Marine <sup>p. 37</sup>
** Fine Art & Specie <sup>p. 37</sup>
*
=== P&C | Focus on reserves ===
Line 1,302 ⟶ 1,372:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Claims and
! style="text-align:left" | %
! class="col-s" style="text-align:right" | FY18
Line 1,354 ⟶ 1,424:
|}
</div>
* Technical reserves definition includes net undiscounted claims reserves and unearned premium reserves <sup>p. 38</sup>.
=== P&C | 2026 Simplified Group Nat Cat reinsurance program 1 ===
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Insurance segment occurrence protection
! style="text-align:left" |
! class="col-s" style="text-align:right" | Retention
! class="col-m" style="text-align:right" | Capacity
|-
| style="text-align:left" | EU Windstorm
|
|
|-
| style="text-align:left" | Europe Flood
|
|
|-
| style="text-align:left" | Europe Earthquake
|
|
|-
| style="text-align:left" | NA Hurricane
|
|
|-
| style="text-align:left" | NA Earthquake
|
|
|-
| style="text-align:left" | Per other perils
|
|
|}
</div>
* Retention levels remained stable in 2026 compared to 2025 <sup>p. 39</sup>.
* (diagram) ''Reinsurance segment'' (illustrative):
*
=== P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026 ===
Line 1,399 ⟶ 1,468:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Group underlying earnings deviation to average Nat Cat charges in 2026
! style="text-align:left" |
! class="col-s" style="text-align:right" | EUR billion
|-
Line 1,431 ⟶ 1,500:
! style="text-align:left" | Year
! class="col-s" style="text-align:right" | EUR billion
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | 2025
Line 1,442 ⟶ 1,511:
|}
</div>
* ''More severe years'' result in a negative deviation in ca. 40% of cases <sup>p. 40</sup>.
* ''
* Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). <sup>p. 40</sup>
=== Table of contents ===
*
*
*
*
=== P&C | Margin analysis ===
Line 1,460 ⟶ 1,526:
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ P&C
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | ''Current Accident Year Undiscounted Technical Margin''
| style="text-align:right" | 2,778
| style="text-align:right" | +707
|-
| style="text-align:left" | ''Current Accident Year Discounting''
| style="text-align:right" | 2,009
| style="text-align:right" | +115
|-
| style="text-align:left" | ''Prior Years' Reserve Development (PYD)''
| style="text-align:right" | 622
| style="text-align:right" | -341
|-
| style="text-align:left" | ''Investment Income''
| style="text-align:right" | 3,988
| style="text-align:right" | +435
|-
| style="text-align:left" | ''Insurance Finance Expenses''
| style="text-align:right" | -1,358
| style="text-align:right" | -235
|-
| style="text-align:left" |
| style="text-align:right" | 8,040
| style="text-align:right" | +681
Line 1,477 ⟶ 1,563:
| style="text-align:right" | -10
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
|}
</div>
* ''Gross earned premiums'' EUR 57,656m (+6%) <sup>p. 42</sup>
*
* ''
* ''
* ''
* ''
* ''
* ''
* ''Discount rate sensitivity'': FY25 sensitivity to current accident year discount rate changes (parallel shift of the full-year average yield curve):
**
** -25bps: -EUR 0.2bn <sup>p. 42</sup>
*
**
=== L&H | Margin analysis ===
*
*
* ''Gross earned premiums'' +10% to EUR 17,416m <sup>p. 43</sup>.
* ''All year combined ratio'' 97.2%, improved 0.1pts <sup>p. 43</sup>.
* ''Long-term technical margin'' +EUR 156m to EUR 2,804m <sup>p. 43</sup>.
** ''CSM release'' +EUR 215m to EUR 2,954m <sup>p. 43</sup>.
** ''Technical experience'' decreased EUR 58m to EUR -150m <sup>p. 43</sup>.
* ''Investment income'' (non-VFA only) decreased EUR 1m to EUR 2,484m <sup>p. 43</sup>.
** ''Average assets'' (FY25) at EUR 98bn with an asset book yield of 2.5% and FY25 reinvestment yield on fixed income assets of 3.8% <sup>p. 43</sup>.
* ''Insurance finance expenses'' (non-VFA only) increased EUR 9m to EUR -1,538m <sup>p. 43</sup>.
** ''Reserves at locked-in rate'' (FY24) at EUR 62bn with a liability book yield of 2.5% <sup>p. 43</sup>.
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Technical
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
Line 1,521 ⟶ 1,607:
| style="text-align:right" | 479
| style="text-align:right" | +60
|-
| style="text-align:left" | Long-term Technical Margin
| style="text-align:right" | 2,804
| style="text-align:right" | +156
|-
| style="text-align:left" | Investment Income (non-VFA only)
Line 1,560 ⟶ 1,621:
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Underlying
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | Change
Line 1,594 ⟶ 1,647:
</div>
*
<div style="overflow-x:auto">
{| class="wikitable fintable"
|+ Life & Health FY25 CSM
! style="text-align:left" | Sensitivity
! class="col-s" style="text-align:right" |
|-
| style="text-align:left" | Baseline
Line 1,630 ⟶ 1,683:
|}
</div>
=== Table of contents ===
* ''Debt and Invested Assets'' <sup>p. 31</sup>
* ''Additional P&C disclosures'' <sup>p. 36</sup>
* ''Additional IFRS17 disclosures'' <sup>p. 41</sup>
* ''Sustainability'' <sup>p. 44</sup>
=== Expanding AXA's role in society: AXA for Progress Index 1 ===
<div style="overflow-x:auto">
{| class="wikitable"
|+ ESG targets and achievements <sup>p. 45</sup>
! style="text-align:left" | Category
! class="col-m" style="text-align:right" | Target
! class="col-m" style="text-align:right" | Achieved in 2025
|-
| style="text-align:left" | Climate transition financing
| class="col-m" style="text-align:right" | EUR 5bn per year
| class="col-m" style="text-align:right" | EUR 6.4bn
|-
| style="text-align:left" | Community resilience financing
| class="col-m" style="text-align:right" | >EUR 500m per year
| class="col-m" style="text-align:right" | EUR 1.4bn
|-
| style="text-align:left" | Transition underwriting (cumulative 2024-2026)
| class="col-m" style="text-align:right" | EUR 6bn in P&C GWP
| class="col-m" style="text-align:right" | EUR 4.6bn
|-
| style="text-align:left" | Climate adaptation solutions (cumulative 2024-2026)
| class="col-m" style="text-align:right" | >20,000
| class="col-m" style="text-align:right" | 19,698 (cumulative 2024-2025)
|-
| style="text-align:left" | Inclusive insurance customers
| class="col-m" style="text-align:right" | >20m by 2026
| class="col-m" style="text-align:right" | 20.6m
|-
| style="text-align:left" | Climate adaptation training
| class="col-m" style="text-align:right" | >80,000 employees by 2026
| class="col-m" style="text-align:right" | 46,420
|-
| style="text-align:left" | Carbon emissions reduction
| class="col-m" style="text-align:right" | -50% by 2030
| class="col-m" style="text-align:right" | -64% against 2019
|-
| style="text-align:left" | Employee volunteering
| class="col-m" style="text-align:right" | 50% of employees by 2026
| class="col-m" style="text-align:right" | 56%
|}
</div>
=== Sustainability Performance & Ratings ===
Line 1,653 ⟶ 1,738:
<div style="overflow-x:auto">
{| class="wikitable"
|+ ESG ratings
! style="text-align:left" | Rating
! class="col-
|-
| style="text-align:left" | S&P Global percentile
| class="col-
|-
| style="text-align:left" | MSCI
| class="col-
|-
| style="text-align:left" | CDP
| class="col-
|-
| style="text-align:left" | Morningstar Sustainalytics
| class="col-
|-
| style="text-align:left" | FTSE Russell
| class="col-
|}
</div>
* The Corporate Sustainability Assessment (CSA) ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (specifically AXA Restricted Shares), with results as of February 6th, 2026 <sup>p. 46</sup>.
* ''Morningstar Sustainalytics rating'': 2025 ESG Risk Rating of 17.0 – Low risk <sup>p. 46</sup>
* ''FTSE Russell score'': 4.3/5 in FTSE4Good Index Series <sup>p. 46</sup>
=== Scope ===
*
*
*
*
**
**
**
**
*
*
*
=== Glossary ===
*
*
*
*
*
*
*
*
*
*
*
*
*
=== February 26, 2026 Thank you Full Year 2025 earnings ===
*
== Abbreviations ==
*
*
*
*
*
* ''AMF'': Autorité des marchés financiers
* ''
* ''AXA IM'': AXA Investment Managers
* ''AXA XL'': AXA Corporate Solutions and XL Catlin
* ''
* ''
* ''
* ''
* ''
* ''CSA'': Corporate Sustainability Assessment
* ''
* ''
* ''
* ''
* ''EOF'': Eligible Own Funds
* ''
* ''ESG'': Environmental, Social, and Governance
* ''ESMA'': European Securities and Markets Authority
* ''
* ''
* ''FX'': Foreign Exchange
* ''GAAP'': Generally Accepted Accounting Principles
* ''
* ''
* ''
* ''HKD'': Hong Kong Dollar
* ''
* ''
* ''IFRS'': International Financial Reporting Standards
* ''
* ''
* ''LATAM'': Latin America
* ''
* ''LTV'': Loan-to-Value
* ''MSCI'': Morgan Stanley Capital International
* ''
* ''NB CSM'': New Business Contractual Service Margin
* ''
* ''
* ''
* ''OCI'': Other Comprehensive Income
* ''
* ''PE'': Private Equity
* ''
* ''
* ''
* ''
* ''SCR'': Solvency Capital Requirement
* ''
* ''SME'': Small and Medium-sized Enterprises
* ''TVOG'': Time Value of Options and Guarantees
* ''
* ''
* ''
* ''VAT'': Value Added Tax
* ''VFA'': Variable Fee Approach
| |||